Assessing the influence of male vaccination on cervical cancer elimination in China under different vaccination coverage scenarios: A modeling study
Cervical cancer caused by human papillomavirus (HPV) infection remains a significant public health challenge in China, where screening and HPV vaccination uptake fall well below World Health Organization’s (WHO) targets. This study aimed to assess the impact of gender-neutral vaccination (GNV) on ce...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2528426 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849319378978340864 |
|---|---|
| author | Ibrahim Diakite Jeffrey Kyle Sujian Situ Wei (Vivian) Wang Xingxing Zhang Yin Wang Rui Bian Hai Bin Wu Xu Sheng Wang Ya-Ting Chen Vincent Daniels |
| author_facet | Ibrahim Diakite Jeffrey Kyle Sujian Situ Wei (Vivian) Wang Xingxing Zhang Yin Wang Rui Bian Hai Bin Wu Xu Sheng Wang Ya-Ting Chen Vincent Daniels |
| author_sort | Ibrahim Diakite |
| collection | DOAJ |
| description | Cervical cancer caused by human papillomavirus (HPV) infection remains a significant public health challenge in China, where screening and HPV vaccination uptake fall well below World Health Organization’s (WHO) targets. This study aimed to assess the impact of gender-neutral vaccination (GNV) on cervical cancer elimination in China at a range of vaccination coverage rates (VCRs) and screening uptake rates. Using a model to project cervical cancer incidence and cases in China over 100 years, we evaluated different vaccination strategies using either a bivalent (2vHPV) or nonavalent (9vHPV) vaccine and estimated the time taken to reach the WHO’s elimination threshold of 4 cases per 100,000 women. Results showed that all GNV strategies were more effective than the corresponding girls-only strategy at preventing cervical cancer, and all 9vHPV-based strategies were more effective than the corresponding 2vHPV-based strategies, especially at lower female VCRs. At a 70% screening uptake and a female VCR of 60%, the fastest predicted disease elimination time (65 years) was achieved using GNV-9vHPV; this timeline was accelerated to 56 years at a female VCR of 90%. The time to elimination using GNV-9vHPV could be accelerated by up to 6 years by adding a catch-up vaccination program or 7 years by increasing the screening rate. These results suggest that updating the current Chinese HPV vaccination program by including males and using a nonavalent vaccine, in conjunction with efforts to increase cervical cancer screening uptake, offers the fastest route to cervical cancer elimination in China, especially while VCRs remain low. |
| format | Article |
| id | doaj-art-02898585615345db8a10e2da5659b9f3 |
| institution | Kabale University |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-02898585615345db8a10e2da5659b9f32025-08-20T03:50:31ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2025-12-0121110.1080/21645515.2025.2528426Assessing the influence of male vaccination on cervical cancer elimination in China under different vaccination coverage scenarios: A modeling studyIbrahim Diakite0Jeffrey Kyle1Sujian Situ2Wei (Vivian) Wang3Xingxing Zhang4Yin Wang5Rui Bian6Hai Bin Wu7Xu Sheng Wang8Ya-Ting Chen9Vincent Daniels10Health Economic and Decision Sciences, Merck & Co., Inc., Rahway, NJ, USAHealth Economic and Decision Sciences, Merck & Co., Inc., Rahway, NJ, USAHealth Economics and Outcomes Research, MSD China Holding Co., Ltd., Shanghai, ChinaOutcomes Research, Merck & Co., Inc., Rahway, NJ, USAMRL Global Medical Affairs, MSD China Holding Co., Ltd., Shanghai, ChinaMRL Global Medical Affairs, MSD China Holding Co., Ltd., Shanghai, ChinaMRL Global Medical Affairs, MSD China Holding Co., Ltd., Shanghai, ChinaMRL Global Medical Affairs, MSD China Holding Co., Ltd., Shanghai, ChinaHealth Economics and Outcomes Research, MSD China Holding Co., Ltd., Shanghai, ChinaOutcomes Research, Merck & Co., Inc., Rahway, NJ, USAHealth Economic and Decision Sciences, Merck & Co., Inc., Rahway, NJ, USACervical cancer caused by human papillomavirus (HPV) infection remains a significant public health challenge in China, where screening and HPV vaccination uptake fall well below World Health Organization’s (WHO) targets. This study aimed to assess the impact of gender-neutral vaccination (GNV) on cervical cancer elimination in China at a range of vaccination coverage rates (VCRs) and screening uptake rates. Using a model to project cervical cancer incidence and cases in China over 100 years, we evaluated different vaccination strategies using either a bivalent (2vHPV) or nonavalent (9vHPV) vaccine and estimated the time taken to reach the WHO’s elimination threshold of 4 cases per 100,000 women. Results showed that all GNV strategies were more effective than the corresponding girls-only strategy at preventing cervical cancer, and all 9vHPV-based strategies were more effective than the corresponding 2vHPV-based strategies, especially at lower female VCRs. At a 70% screening uptake and a female VCR of 60%, the fastest predicted disease elimination time (65 years) was achieved using GNV-9vHPV; this timeline was accelerated to 56 years at a female VCR of 90%. The time to elimination using GNV-9vHPV could be accelerated by up to 6 years by adding a catch-up vaccination program or 7 years by increasing the screening rate. These results suggest that updating the current Chinese HPV vaccination program by including males and using a nonavalent vaccine, in conjunction with efforts to increase cervical cancer screening uptake, offers the fastest route to cervical cancer elimination in China, especially while VCRs remain low.https://www.tandfonline.com/doi/10.1080/21645515.2025.2528426Cervical cancerhuman papillomavirusHPV vaccinationgender-neutral vaccinationChina |
| spellingShingle | Ibrahim Diakite Jeffrey Kyle Sujian Situ Wei (Vivian) Wang Xingxing Zhang Yin Wang Rui Bian Hai Bin Wu Xu Sheng Wang Ya-Ting Chen Vincent Daniels Assessing the influence of male vaccination on cervical cancer elimination in China under different vaccination coverage scenarios: A modeling study Human Vaccines & Immunotherapeutics Cervical cancer human papillomavirus HPV vaccination gender-neutral vaccination China |
| title | Assessing the influence of male vaccination on cervical cancer elimination in China under different vaccination coverage scenarios: A modeling study |
| title_full | Assessing the influence of male vaccination on cervical cancer elimination in China under different vaccination coverage scenarios: A modeling study |
| title_fullStr | Assessing the influence of male vaccination on cervical cancer elimination in China under different vaccination coverage scenarios: A modeling study |
| title_full_unstemmed | Assessing the influence of male vaccination on cervical cancer elimination in China under different vaccination coverage scenarios: A modeling study |
| title_short | Assessing the influence of male vaccination on cervical cancer elimination in China under different vaccination coverage scenarios: A modeling study |
| title_sort | assessing the influence of male vaccination on cervical cancer elimination in china under different vaccination coverage scenarios a modeling study |
| topic | Cervical cancer human papillomavirus HPV vaccination gender-neutral vaccination China |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2025.2528426 |
| work_keys_str_mv | AT ibrahimdiakite assessingtheinfluenceofmalevaccinationoncervicalcancereliminationinchinaunderdifferentvaccinationcoveragescenariosamodelingstudy AT jeffreykyle assessingtheinfluenceofmalevaccinationoncervicalcancereliminationinchinaunderdifferentvaccinationcoveragescenariosamodelingstudy AT sujiansitu assessingtheinfluenceofmalevaccinationoncervicalcancereliminationinchinaunderdifferentvaccinationcoveragescenariosamodelingstudy AT weivivianwang assessingtheinfluenceofmalevaccinationoncervicalcancereliminationinchinaunderdifferentvaccinationcoveragescenariosamodelingstudy AT xingxingzhang assessingtheinfluenceofmalevaccinationoncervicalcancereliminationinchinaunderdifferentvaccinationcoveragescenariosamodelingstudy AT yinwang assessingtheinfluenceofmalevaccinationoncervicalcancereliminationinchinaunderdifferentvaccinationcoveragescenariosamodelingstudy AT ruibian assessingtheinfluenceofmalevaccinationoncervicalcancereliminationinchinaunderdifferentvaccinationcoveragescenariosamodelingstudy AT haibinwu assessingtheinfluenceofmalevaccinationoncervicalcancereliminationinchinaunderdifferentvaccinationcoveragescenariosamodelingstudy AT xushengwang assessingtheinfluenceofmalevaccinationoncervicalcancereliminationinchinaunderdifferentvaccinationcoveragescenariosamodelingstudy AT yatingchen assessingtheinfluenceofmalevaccinationoncervicalcancereliminationinchinaunderdifferentvaccinationcoveragescenariosamodelingstudy AT vincentdaniels assessingtheinfluenceofmalevaccinationoncervicalcancereliminationinchinaunderdifferentvaccinationcoveragescenariosamodelingstudy |